دورية أكاديمية
أعرض في EDS

CRISPR/Cas9-generated mouse model with humanizing single-base substitution in the Gnao1 for safety studies of RNA therapeutics.

التفاصيل البيبلوغرافية
العنوان: CRISPR/Cas9-generated mouse model with humanizing single-base substitution in the Gnao1 for safety studies of RNA therapeutics.
المؤلفون: Polikarpova AV; Laboratory of Modeling and Gene Therapy of Hereditary Diseases, Institute of Gene Biology Russian Academy of Sciences, Moscow, Russia.; Marlin Biotech, Sochi, Russia., Egorova TV; Laboratory of Modeling and Gene Therapy of Hereditary Diseases, Institute of Gene Biology Russian Academy of Sciences, Moscow, Russia.; Marlin Biotech, Sochi, Russia., Lunev EA; Laboratory of Modeling and Gene Therapy of Hereditary Diseases, Institute of Gene Biology Russian Academy of Sciences, Moscow, Russia.; Marlin Biotech, Sochi, Russia.; Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russia., Tsitrina AA; Koltzov Institute of Developmental Biology Russian Academy of Sciences, Moscow, Russia., Vassilieva SG; Laboratory of Modeling and Gene Therapy of Hereditary Diseases, Institute of Gene Biology Russian Academy of Sciences, Moscow, Russia.; Marlin Biotech, Sochi, Russia., Savchenko IM; Marlin Biotech, Sochi, Russia.; Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russia., Silaeva YY; Core Facility Center, Institute of Gene Biology Russian Academy of Sciences, Moscow, Russia., Deykin AV; Marlin Biotech, Sochi, Russia.; Core Facility Center, Institute of Gene Biology Russian Academy of Sciences, Moscow, Russia.; Laboratory of Genetic Technologies and Genome Editing for Biomedicine and Animal Health, Joint Center for Genetic Technologies, Belgorod National Research University, Belgorod, Russia., Bardina MV; Laboratory of Modeling and Gene Therapy of Hereditary Diseases, Institute of Gene Biology Russian Academy of Sciences, Moscow, Russia.; Marlin Biotech, Sochi, Russia.; Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russia.
المصدر: Frontiers in genome editing [Front Genome Ed] 2023 Apr 03; Vol. 5, pp. 1034720. Date of Electronic Publication: 2023 Apr 03 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101775540 Publication Model: eCollection Cited Medium: Internet ISSN: 2673-3439 (Electronic) Linking ISSN: 26733439 NLM ISO Abbreviation: Front Genome Ed Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Lausanne, Switzerland : Frontiers Media S.A., [2020]-
مستخلص: The development of personalized medicine for genetic diseases requires preclinical testing in the appropriate animal models. GNAO1 encephalopathy is a severe neurodevelopmental disorder caused by heterozygous de novo mutations in the GNAO1 gene. GNAO1 c.607 G>A is one of the most common pathogenic variants, and the mutant protein Gαo-G203R likely adversely affects neuronal signaling. As an innovative approach, sequence-specific RNA-based therapeutics such as antisense oligonucleotides or effectors of RNA interference are potentially applicable for selective suppression of the mutant GNAO1 transcript. While in vitro validation can be performed in patient-derived cells, a humanized mouse model to rule out the safety of RNA therapeutics is currently lacking. In the present work, we employed CRISPR/Cas9 technology to introduce a single-base substitution into exon 6 of the Gnao1 to replace the murine Gly203-coding triplet (GGG) with the codon used in the human gene (GGA). We verified that genome-editing did not interfere with the Gnao1 mRNA or Gαo protein synthesis and did not alter localization of the protein in the brain structures. The analysis of blastocysts revealed the off-target activity of the CRISPR/Cas9 complexes; however, no modifications of the predicted off-target sites were detected in the founder mouse. Histological staining confirmed the absence of abnormal changes in the brain of genome-edited mice. The created mouse model with the "humanized" fragment of the endogenous Gnao1 is suitable to rule out unintended targeting of the wild-type allele by RNA therapeutics directed at lowering GNAO1 c.607 G>A transcripts.
Competing Interests: AP, TE, EL, SV, IS, AD, and MB were employed by Marlin Biotech. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor MS declared a shared affiliation with the authors at the time of review.
(Copyright © 2023 Polikarpova, Egorova, Lunev, Tsitrina, Vassilieva, Savchenko, Silaeva, Deykin and Bardina.)
References: Neurosignals. 2009;17(1):23-41. (PMID: 19212138)
Int J Mol Med. 2014 Mar;33(3):589-96. (PMID: 24366063)
Methods Mol Biol. 2017;1641:101-114. (PMID: 28748459)
Sci Rep. 2022 Jan 17;12(1):848. (PMID: 35039573)
Methods Mol Biol. 2022;2434:267-279. (PMID: 35213024)
Nat Methods. 2014 Feb;11(2):122-3. (PMID: 24481216)
Brain Res. 2002 Jun 21;941(1-2):62-71. (PMID: 12031548)
Nature. 2016 May 5;533(7601):125-9. (PMID: 27120160)
Nature. 2013 Sep 12;501(7466):217-21. (PMID: 23934111)
Science. 2013 Oct 4;342(6154):111-4. (PMID: 24092743)
Int J Mol Sci. 2022 Mar 01;23(5):. (PMID: 35269876)
Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3269-74. (PMID: 9501252)
Nat Commun. 2019 Apr 23;10(1):1845. (PMID: 31015419)
Mov Disord. 2022 Dec;37(12):2464-2466. (PMID: 36273395)
Mol Ther Methods Clin Dev. 2019 Oct 28;15:343-358. (PMID: 31828177)
Epileptic Disord. 2017 Mar 1;19(1):67-75. (PMID: 28202424)
Mol Phylogenet Evol. 2015 Oct;91:27-40. (PMID: 26002831)
Pharmaceutics. 2022 Aug 16;14(8):. (PMID: 36015334)
Brain Res. 1999 Aug 7;837(1-2):117-26. (PMID: 10433994)
Neuron. 2017 Jun 21;94(6):1056-1070. (PMID: 28641106)
Am J Hum Genet. 2013 Sep 5;93(3):496-505. (PMID: 23993195)
Mol Cell Neurosci. 2021 Jan;110:103585. (PMID: 33358996)
Dev Dyn. 2014 Dec;243(12):1632-6. (PMID: 25160973)
Trends Genet. 2022 Jun;38(6):613-626. (PMID: 35303998)
BMC Biotechnol. 2014 Jul 21;14:69. (PMID: 25042988)
PLoS One. 2019 Jan 30;14(1):e0211384. (PMID: 30699165)
J Clin Invest. 2019 Dec 2;129(12):5568-5583. (PMID: 31557132)
N Engl J Med. 2019 Oct 24;381(17):1644-1652. (PMID: 31597037)
Proc Natl Acad Sci U S A. 1986 Jun;83(12):4561-5. (PMID: 3086888)
Neurobiol Dis. 2018 Aug;116:131-141. (PMID: 29758257)
Histochem Cell Biol. 2001 Aug;116(2):149-59. (PMID: 11685543)
Cell Death Dis. 2022 Jul 23;13(7):644. (PMID: 35871216)
Mol Ther Nucleic Acids. 2017 Sep 15;8:508-519. (PMID: 28918051)
Blood. 2021 Mar 4;137(9):1181-1191. (PMID: 32898863)
J Vis Exp. 2014 Sep 15;(91):51863. (PMID: 25286085)
Sci Transl Med. 2018 Oct 3;10(461):. (PMID: 30282695)
Mamm Genome. 2019 Aug;30(7-8):173-191. (PMID: 31203387)
Sci Rep. 2017 Feb 17;7:42661. (PMID: 28209967)
Mamm Genome. 2014 Jun;25(5-6):202-10. (PMID: 24700286)
Sci Rep. 2017 Feb 08;7:42244. (PMID: 28176880)
Biochem J. 2007 Apr 1;403(1):119-27. (PMID: 17125467)
Cell Rep. 2021 Feb 2;34(5):108718. (PMID: 33535037)
J Biol Chem. 2002 Nov 22;277(47):45558-65. (PMID: 12244051)
Neurology. 2017 Aug 22;89(8):762-770. (PMID: 28747448)
Gene. 2018 Jul 30;665:67-73. (PMID: 29709639)
Eur J Hum Genet. 2016 Jan;24(1):129-34. (PMID: 25966631)
Acta Neuropathol Commun. 2022 Jan 28;10(1):9. (PMID: 35090564)
FASEB J. 2020 Dec;34(12):16601-16621. (PMID: 33107105)
J Pharmacol Exp Ther. 2020 Apr;373(1):24-33. (PMID: 31907305)
Sci Rep. 2019 Mar 18;9(1):4811. (PMID: 30886178)
Nat Rev Drug Discov. 2020 Jul;19(7):441-442. (PMID: 32341501)
Mol Ther. 2020 Jul 8;28(7):1706-1716. (PMID: 32353324)
Nat Rev Genet. 2018 Dec;19(12):770-788. (PMID: 30323312)
Sci Adv. 2022 Oct 7;8(40):eabn9350. (PMID: 36206333)
Epilepsia. 2019 Mar;60(3):406-418. (PMID: 30682224)
Mol Biol (Mosk). 2010 Mar-Apr;44(2):311-22. (PMID: 20586192)
Mol Biol (Mosk). 2022 Jul-Aug;56(4):604-618. (PMID: 35964317)
Mol Ther Nucleic Acids. 2018 Sep 7;12:75-88. (PMID: 30195799)
Proc Natl Acad Sci U S A. 2016 Sep 27;113(39):10974-9. (PMID: 27625425)
Oncotarget. 2017 Oct 25;9(35):23846-23847. (PMID: 29844856)
Pediatr Neurol. 2021 Aug;121:28-32. (PMID: 34139551)
Front Neurosci. 2020 Sep 18;14:580179. (PMID: 33071748)
J Neurosci. 1996 Feb 1;16(3):909-18. (PMID: 8558259)
J Neurophysiol. 2022 Mar 1;127(3):607-622. (PMID: 35080448)
Dis Model Mech. 2019 Apr 25;12(4):. (PMID: 31028078)
PLoS One. 2019 Jan 25;14(1):e0211066. (PMID: 30682176)
Biomedicines. 2020 Oct 06;8(10):. (PMID: 33036271)
Mol Ther Nucleic Acids. 2018 Dec 7;13:291-302. (PMID: 30321816)
Mol Ther. 2018 Apr 4;26(4):947-962. (PMID: 29503201)
Hum Mol Genet. 2022 Feb 21;31(4):510-522. (PMID: 34508586)
Dis Model Mech. 2019 Oct 1;13(2):. (PMID: 31591145)
Mol Brain. 2019 Jun 20;12(1):57. (PMID: 31221179)
J Mol Med (Berl). 2020 May;98(5):615-632. (PMID: 32198625)
Parkinsonism Relat Disord. 2022 Oct;103:112-114. (PMID: 36096018)
PLoS One. 2011;6(10):e26194. (PMID: 22031823)
Mol Med Rep. 2017 Jun;15(6):3879-3884. (PMID: 28393214)
Sci Rep. 2017 Jan 18;7:40638. (PMID: 28098181)
Front Neuroanat. 2021 Jun 25;15:686279. (PMID: 34248508)
فهرسة مساهمة: Keywords: CRISPR/Cas9; GNAO1 encephalopathy; genetically modified mice; genome editing; personalized medicine
تواريخ الأحداث: Date Created: 20230420 Latest Revision: 20230421
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10106585
DOI: 10.3389/fgeed.2023.1034720
PMID: 37077890
قاعدة البيانات: MEDLINE
الوصف
تدمد:2673-3439
DOI:10.3389/fgeed.2023.1034720